This handout is for pediatric community-acquired pneumonia (cap). Your care team identified this based on: fever + cough + age-band tachypnea in a child (pids/idsa 2011 bradley; who imci 2025).
Other reasons your team may use this plan: retractions / nasal flaring / grunting / accessory muscle use (who imci 2025; bts 2024); spo2 <92% in a child with respiratory illness (pids/idsa 2011; bts 2024); new infiltrate on cxr or consolidation on lung ultrasound (pids/idsa 2011; bts 2024).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| amoxicillin | 90 mg/kg/day PO divided BID or TID (max 4 g/day) | PO | q8-12h × 5 days | PIDS/IDSA 2011 first-line; high-dose covers DRSP; CAP-IT 2021 validated 3-day course in mild, 5-day standard |
| azithromycin | 10 mg/kg PO day 1 (max 500 mg) then 5 mg/kg/day (max 250 mg) days 2-5 | PO | daily × 5 days | Reserved for severe β-lactam allergy or atypical concern; macrolide resistance up to 10-20% in some regions |
Plan: PIDS/IDSA pediatric CAP empiric antibiotics — outpatient → ward → PICU; age + immunization + severity-tiered (PIDS/IDSA 2011 Bradley + 2024 update; WHO IMCI 2025; BTS 2024)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
PCP follow-up 1-2 wk; CXR at 4-6 wk for round / lobar / non-resolving pneumonia (BTS 2024); immunization catch-up (PCV / Hib / influenza / COVID) per ACIP 2025; smoke-exposure cessation; immunology workup if recurrent / non-resolving; pulmonology referral if structural concern (PIDS/IDSA 2011; AAP Bright Futures)
Guideline: PIDS/IDSA 2011 pediatric CAP guideline (Bradley) + 2024 short-course update (CAP-IT 2021) + WHO IMCI 2025 + BTS 2024 pediatric pneumonia + SSC Pediatrics 2020/2024 + AAP 2021 Pantell febrile infant (neonatal routing)